Agenda
JAK Inhibition in Improving Outcomes for Patients With Myelofibrosis
- Diagnostic criteria and risk assessment
- First-line treatment of myelofibrosis
Recognizing Patterns of Suboptimal Response to First-Line Myelofibrosis Treatment
- Intolerance
- Resistance
- Overlapping features and response assessment
Second-Line Treatment Options
- Best practices for transitioning to second-line therapy
- Second-line JAK inhibitors
- Emerging Agents
Managing Disease-Related and Treatment-Related Symptoms while Partnering with Patients
Events
Date / Time
Event Details
Faculty
Program Chair
Raajit Rampal, MD, PhD
Associate Member
Associate Attending Physician
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Program Chair
Srdan Verstovsek, MD, PhD
Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas
Faculty
Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Program Overview
Gain expert insight on current best practices and emerging strategies for first-line and subsequent treatment of myelofibrosis in these interactive, expert led 1-hour CME/CNE/CPE-certified workshops.
Goal Statement
The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in the use of evidence-based and guideline-directed best practices in the care of patients with MF.
Target Audience
TThis program is intended for community-based medical hematologists/oncologists, advanced practice providers, nurses, pharmacists, physician assistants/physician associates, and other healthcare professionals involved in the treatment of patients with myelofibrosis.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Plan first line therapy for patients with MF based on available data and expert recommendations, taking risk stratification, platelet counts, and symptom burden into account
- Recognize the symptoms and patterns of suboptimal first line treatment response in patients with MF, including treatment intolerance and treatment resistance
- Plan evidence-based therapeutic strategies for patients with MF and a suboptimal response to first-line JAK inhibitor therapy
- Integrate supportive care plans into practice designed to monitor and manage treatment-related toxicities from new or novel MF treatments
Accreditation
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-030-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Assistant/Physician Associate Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.